Sustained release 4-aminopyridine (Fampyra) in cerebellar gait disorder
Phase of Trial: Phase III
Latest Information Update: 13 Nov 2018
At a glance
- Drugs Fampridine (Primary)
- Indications Cerebellar ataxia; Gait disturbances
- Focus Therapeutic Use
- Acronyms FACEG
- 07 Dec 2016 Status changed from recruiting to completed.
- 11 Dec 2013 New source identified and integrated (German Clinical Trials Register, DRKS00004783).
- 28 Mar 2013 New trial record